Royce & Associates LP Purchases 134,016 Shares of SiBone $SIBN

Royce & Associates LP raised its position in shares of SiBone (NASDAQ:SIBN) by 82.7% during the 4th quarter, HoldingsChannel.com reports. The fund owned 296,067 shares of the company’s stock after acquiring an additional 134,016 shares during the period. Royce & Associates LP’s holdings in SiBone were worth $5,838,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Hussman Strategic Advisors Inc. bought a new stake in SiBone during the 4th quarter valued at approximately $1,656,000. First Eagle Investment Management LLC boosted its position in SiBone by 36.6% during the 3rd quarter. First Eagle Investment Management LLC now owns 484,261 shares of the company’s stock valued at $7,128,000 after acquiring an additional 129,723 shares in the last quarter. Impax Asset Management Group plc boosted its position in SiBone by 17.1% during the 4th quarter. Impax Asset Management Group plc now owns 1,200,010 shares of the company’s stock valued at $23,664,000 after acquiring an additional 175,000 shares in the last quarter. Y Intercept Hong Kong Ltd boosted its position in SiBone by 337.7% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 83,369 shares of the company’s stock valued at $1,227,000 after acquiring an additional 64,322 shares in the last quarter. Finally, First Light Asset Management LLC boosted its position in SiBone by 9.5% during the 3rd quarter. First Light Asset Management LLC now owns 1,917,903 shares of the company’s stock valued at $28,232,000 after acquiring an additional 166,902 shares in the last quarter. 98.11% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CFO Anshul Maheshwari sold 3,318 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $12.87, for a total value of $42,702.66. Following the sale, the chief financial officer directly owned 263,148 shares of the company’s stock, valued at $3,386,714.76. The trade was a 1.25% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Laura Francis sold 14,957 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $14.71, for a total value of $220,017.47. Following the completion of the sale, the chief executive officer directly owned 503,444 shares in the company, valued at approximately $7,405,661.24. This represents a 2.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 29,572 shares of company stock valued at $418,831. 4.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

SIBN has been the topic of several research reports. Truist Financial reaffirmed a “buy” rating and set a $18.00 price objective (down from $20.00) on shares of SiBone in a research report on Tuesday, May 12th. TD Cowen cut their price objective on SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. Finally, Wall Street Zen cut SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, SiBone presently has a consensus rating of “Moderate Buy” and an average price target of $23.00.

SiBone Stock Performance

Shares of SIBN opened at $14.10 on Friday. The company has a quick ratio of 8.34, a current ratio of 9.99 and a debt-to-equity ratio of 0.20. The business’s 50 day moving average price is $13.53 and its 200-day moving average price is $16.05. SiBone has a 52 week low of $11.48 and a 52 week high of $21.89. The stock has a market cap of $625.32 million, a P/E ratio of -36.15 and a beta of 0.67.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. SiBone had a negative return on equity of 9.56% and a negative net margin of 8.10%.The firm had revenue of $52.59 million for the quarter, compared to analysts’ expectations of $51.16 million. Equities research analysts anticipate that SiBone will post -0.44 earnings per share for the current fiscal year.

SiBone Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.